AUTL Stock Analysis: Buy, Sell, or Hold?
AUTL - Autolus Therapeutics plc American Depositary Share
$2.35
-0.06 (-2.70%)
▼
5d:
+2.85%
30d:
+61.72%
90d:
+37.94%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When AUTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AUTL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AUTL shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: AUTL is currently trading at $2.35, which is considered extended relative to its 30-day fair value range of $1.49 to $2.27.
Technical Outlook: Technically, AUTL is in a uptrend. Immediate support is located at $2.02, while resistance sits at $2.58.
Market Sentiment: AUTL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.72 (+262.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AUTL is in a uptrend. Immediate support is located at $2.02, while resistance sits at $2.58.
Market Sentiment: AUTL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.72 (+262.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.49 -
$2.27
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 262.0% below Wall St target ($8.72)
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.49 -
$2.27
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.02
Resistance Level
$2.58
Current Trend
Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.85
Wall Street Target
$8.73
(+262.0%)
Revenue Growth (YoY)
83655.2%
Share & Embed Analysis
Last updated: August 24, 2026 3:04 PM ET
Data refreshes hourly during market hours. Next update: 4:04 PM
Data refreshes hourly during market hours. Next update: 4:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AUTL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 46 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 45 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 68 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
13 analysts |
$19 | 51 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 32 SELL |
